Another day, another warning from a prescription drug. GlaxoSmithKline's "Avandia" diabetes drug (aka, rosiglitazone) is being hailed as raising the risk of a heart attack and heart death by 43% and 64%, respectively, when taken for diabetes treatment.

It continues to baffle me how synthetic drugs continue to be linked t heart problems, although GSK says in this case that the benefits outweigh the detriments. I'd like to see the details on how it comes by that assessment, though.

Dr. Steve Nissen, whom I've covered before, said that "Unfortunately, rosiglitazone appears to increase, rather than decrease, the most serious complication of diabetes, heart disease."

For more information on preventing or managing diabetes, please visit The Diabetes Blog.